2026 Summer Intern - AI Biology and Translation jobs in United States
cer-icon
Apply on Employer Site
company-logo

Genentech · 17 hours ago

2026 Summer Intern - AI Biology and Translation

Genentech is a biotechnology company that develops statistical and AI tools to understand the biology of disease. They are seeking a Summer Intern to develop and test a computational pipeline for genome-wide association studies and leverage models to identify causal variants and genes.

BiotechnologyLife ScienceManufacturing
check
Comp. & Benefits
check
H1B Sponsor Likelynote

Responsibilities

Developing and test a computational pipeline for functional fine-mapping of genome-wide association studies
Leverage proprietary sequence-to-function models to better identify causal variants and genes
Comparing these results with fine-mapping from other strategies

Qualification

ProgrammingStatisticsGitCommunication skillsCollaboration skillsInterpersonal skills

Required

Must be pursuing a Master's Degree (enrolled student)
Must be pursuing a PhD (enrolled student)
Computational Biology, Genetics, Computer Science
Programming (C, R, or Python preferred)
Statistics/Statistical Genetics

Preferred

Excellent communication, collaboration, and interpersonal skills
Complements our culture and the standards that guide our daily behavior & decisions: Integrity, Courage, and Passion
Git

Benefits

Paid holiday time off benefits

Company

Genentech

company-logo
Genentech is a biotechnology research company that specializes in genetic testing and personalized medicines.

H1B Sponsorship

Genentech has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (167)
2024 (148)
2023 (150)
2022 (178)
2021 (121)
2020 (158)

Funding

Current Stage
Public Company
Total Funding
unknown
2009-03-26Acquired
1999-07-20IPO
1976-01-01Series Unknown

Leadership Team

leader-logo
Ashley Magargee
Chief Executive Officer
linkedin
leader-logo
Michael Laird
Vice President, Global MSAT Drug Substance Biologics Technology and Commercial Products Support
linkedin
Company data provided by crunchbase